^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DPV-001

    i
    Other names: DPV-001, autophagosome-enriched DRibble vaccine, DRibble vaccine, DPV 001, DPV001
    Associations

    News

    Trials
    Company:
    UbiVac
    Drug class:
    TLR agonist
    Related drugs:
    Associations

    News

    Trials
    5ms
    Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC (clinicaltrials.gov)
    P1, N=56, Recruiting, Providence Health & Services | Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Dec 2027 | Trial primary completion date: Dec 2023 --> Dec 2025
    Enrollment open • Trial completion date • Trial primary completion date • Checkpoint inhibition • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Zynyz (retifanlimab-dlwr) • DPV-001 • ragifilimab (INCAGN1876)
    over1year
    Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC (clinicaltrials.gov)
    P1, N=56, Active, not recruiting, Providence Health & Services | Recruiting --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Zynyz (retifanlimab-dlwr) • DPV-001 • ragifilimab (INCAGN1876)
    3years
    Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC (clinicaltrials.gov)
    P1, N=56, Recruiting, Providence Health & Services | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    CD4 (CD4 Molecule)
    |
    Zynyz (retifanlimab-dlwr) • DPV-001 • ragifilimab (INCAGN1876)